RU58841 is a topical anti-androgen used for male and female pattern hair loss. You apply it as a solution to the scalp once a day and it sits on the androgen receptors in your hair follicles, blocking DHT from binding and triggering the miniaturisation process that thins hair over time. Unlike finasteride, it doesn't lower DHT anywhere else in your body, the whole point of the molecule is that it gets used up locally and barely makes it into systemic circulation.
It get the scalp-level effect of an anti-androgen without the systemic sexual, mood, or hormonal side effects that Finasteride and Dutasteride can cause in a meaningful minority of users. It's the option people reach for when they want to keep their hair but don't want to gamble with their libido, mental clarity, or fertility. It's also the option women with pattern hair loss reach for when oral anti-androgens are off the table due to side effects, pregnancy plans, or contraception conflicts.
It was developed by Roussel Uclaf in France in the early 1990s, advanced through Phase II human trials by ProStrakan in the 2000s with promising results, then quietly discontinued for non-safety business reasons. No company has picked it up since. That's why it sits in the research-chemical bucket today, sold as raw powder you mix into a solution yourself or as pre-mixed bottles from grey-market vendors of variable quality.
The first 4-8 weeks usually show very little visible change. Some users notice an initial shed (similar to the minoxidil shed) as follicles shift from telogen back into anagen, this is a positive sign even though it looks alarming. By month 3, most users see thicker existing hair and slowing of further loss. By month 6, regrowth in previously thinned areas becomes visible in photos taken under consistent lighting. The macaque data showed peak effect somewhere between month 5 and month 7 and continued maintenance with ongoing treatment.
It's not a one-time fix. The day you stop applying it, the protection ends and the underlying genetics take over again. Most users who get good results from RU58841 commit to it long-term, the same way finasteride users do. If you're not prepared to use a topical compound for years, the cost-benefit doesn't favour this one.
If you see no improvement by month 6 of consistent daily use, you're unlikely to be a responder and continuing is mostly burning money. The non-responder rate is probably similar to finasteride's (around 10-20% of users), though we don't have clean trial data on this for RU specifically.